A post from the blog Armstrong Economics that has been widely shared on Facebook claims that the “CDC admits that COVID tests are invalid.” According to the article: “The Centers for Disease Control (CDC) is finally withdrawing the PCR test for COVID for it is seriously flawed and is incapable of distinguishing between the COVID and influenza viruses.”
This is false.
As proof for the claim, the article includes a statement from the CDC from July 2021, about “changes to CDC RT-PCR for SARS-CoV-2 Testing.”
This statement declares that the CDC is withdrawing a request to the FDA for emergency use authorization for one specific COVID test and said it would be retired. However, it is not evidence that the PCR test for COVID-19 is flawed.
The CDC issued a statement in August 2021 with “clarifications about the Retirement of the CDC 2019 Novel Coronavirus (2019-nCov) Real-Time RT-PCR Diagnostic Panel.”
The statement made clear that the July 2021announcement, later cited in the viral article, meant that the CDC was retiring the CDC 2019 Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel. In the statement the CDC explained it was retiring the test“because the U.S. Food and Drug Administration (FDA) has authorized hundreds of other SARS-CoV-2 diagnostic tests, many of which are now higher throughput or can test for more than one illness at a time. At the time CDC deployed the 2019-nCoV Real-Time RT-PCR Diagnostic Panel, there were no other FDA-authorized methods available within the United States.”
The CDC clarified that the July announcement did not mean that the CDC 2019 Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel failed or that it was revoked by the FDA. “There are no performance concerns with this test. The CDC 2019 Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel is a highly accurate test. It has been used to successfully detect SARS-CoV-2 since February 2020.”
Lastly, the viral article also claims that the “CDC has finally admitted that the PCR test cannot even differentiate between SARS-CoV-2 and influenza viruses.” The CDC addressed this matter as well in its August 2021 statement, saying that: “The CDC 2019-nCoV Real-Time RT-PCR Diagnostic Panel does not confuse influenza with SARS-CoV-2. It is a highly accurate test that detects the presence or absence of SARS-CoV-2 viral genetic material within a patient specimen.” The CDC also added that the test in question “was specifically designed to only detect SARS-CoV-2 viral genetic material. It does not detect influenza or differentiate between influenza and SARS-CoV-2. The presence of influenza viral genetic material within a specimen will not cause a false positive result.”
If you have a claim you would like to see us fact check, please send us an email at factcheck@thedispatch.com. If you would like to suggest a correction to this piece or any other Dispatch article, please email corrections@thedispatch.com.
Please note that we at The Dispatch hold ourselves, our work, and our commenters to a higher standard than other places on the internet. We welcome comments that foster genuine debate or discussion—including comments critical of us or our work—but responses that include ad hominem attacks on fellow Dispatch members or are intended to stoke fear and anger may be moderated.
You are currently using a limited time guest pass and do not have access to commenting. Consider subscribing to join the conversation.
With your membership, you only have the ability to comment on The Morning Dispatch articles. Consider upgrading to join the conversation everywhere.